Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center

Abstract

Infliximab is safe and effective for treating pediatric patients with CD. A steroid-sparing effect was demonstrated. The most common adverse reaction to infliximab was infusion reaction. These reactions did not preclude further use of the agent. Serious infections were seen in a small number of patients.